Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Accumulated Expenses (2016 - 2018)

Vanda Pharmaceuticals' Accumulated Expenses history spans 9 years, with the latest figure at $3.4 million for Q1 2018.

  • On a quarterly basis, Accumulated Expenses fell 88.49% to $3.4 million in Q1 2018 year-over-year; TTM through Mar 2018 was $3.4 million, a 88.49% decrease, with the full-year FY2017 number at $5.3 million, up 16.86% from a year prior.
  • Accumulated Expenses hit $3.4 million in Q1 2018 for Vanda Pharmaceuticals, down from $5.3 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for VNDA hit a ceiling of $43.6 million in Q2 2015 and a floor of $602000.0 in Q4 2014.
  • Historically, Accumulated Expenses has averaged $12.7 million across 5 years, with a median of $4.1 million in 2016.
  • Biggest five-year swings in Accumulated Expenses: soared 5805.32% in 2015 and later crashed 94.71% in 2016.
  • Tracing VNDA's Accumulated Expenses over 5 years: stood at $602000.0 in 2014, then soared by 5805.32% to $35.6 million in 2015, then tumbled by 87.19% to $4.6 million in 2016, then grew by 16.86% to $5.3 million in 2017, then tumbled by 35.24% to $3.4 million in 2018.
  • Business Quant data shows Accumulated Expenses for VNDA at $3.4 million in Q1 2018, $5.3 million in Q4 2017, and $3.6 million in Q3 2017.